Aditya Bagrodia

Okay, we'll see you in six months with a PSA and a testosterone. And I'd like to think that, you know, it's a bit more advanced than that. So maybe you kind of alluded to it, you know, obviously this is prostate cancer. It is addicted to testosterone. We've got to get those testosterone level down to castrate.

Can you just talk a little bit about, maybe we start with disease states, early disease states, all the way to advanced disease states. When you think about this, how do you kind of think about when ADT might be appropriate? Yeah.

Can you just talk a little bit about, maybe we start with disease states, early disease states, all the way to advanced disease states. When you think about this, how do you kind of think about when ADT might be appropriate? Yeah.

Can you just talk a little bit about, maybe we start with disease states, early disease states, all the way to advanced disease states. When you think about this, how do you kind of think about when ADT might be appropriate? Yeah.

Yeah, and I think that really kind of perfectly captures that ADT kind of has a role potentially across the disease spectrum. And maybe just one question, primary ADT, is there a unique patient these days that that might still be an option?

Yeah, and I think that really kind of perfectly captures that ADT kind of has a role potentially across the disease spectrum. And maybe just one question, primary ADT, is there a unique patient these days that that might still be an option?

Yeah, and I think that really kind of perfectly captures that ADT kind of has a role potentially across the disease spectrum. And maybe just one question, primary ADT, is there a unique patient these days that that might still be an option?

localized prostate cancer, really not a candidate for surgery, radiation. Are there patients that you might be considering primary agency for?

localized prostate cancer, really not a candidate for surgery, radiation. Are there patients that you might be considering primary agency for?

localized prostate cancer, really not a candidate for surgery, radiation. Are there patients that you might be considering primary agency for?

Totally. Couldn't agree more. And not to overgeneralize, many times it's the elder, sicker, infirm patients where they've still maybe got some gas left in the tank. You don't want to say good luck and good night, but surgery or radiation, you know, maybe due to their underlying urinary symptoms, et cetera, aren't going to be great options. Okay, fantastic.

Totally. Couldn't agree more. And not to overgeneralize, many times it's the elder, sicker, infirm patients where they've still maybe got some gas left in the tank. You don't want to say good luck and good night, but surgery or radiation, you know, maybe due to their underlying urinary symptoms, et cetera, aren't going to be great options. Okay, fantastic.

Totally. Couldn't agree more. And not to overgeneralize, many times it's the elder, sicker, infirm patients where they've still maybe got some gas left in the tank. You don't want to say good luck and good night, but surgery or radiation, you know, maybe due to their underlying urinary symptoms, et cetera, aren't going to be great options. Okay, fantastic.

So, you know, I love the way you mentioned that it's the duration, the intensity, and the kind of intent of therapy that are largely modulating this. And maybe we can start out with, you know, four to six months ADT for generally unfavorable intermediate risk prostate cancer. What agents, any kind of major preference? And maybe I'll just throw this out there.

So, you know, I love the way you mentioned that it's the duration, the intensity, and the kind of intent of therapy that are largely modulating this. And maybe we can start out with, you know, four to six months ADT for generally unfavorable intermediate risk prostate cancer. What agents, any kind of major preference? And maybe I'll just throw this out there.

So, you know, I love the way you mentioned that it's the duration, the intensity, and the kind of intent of therapy that are largely modulating this. And maybe we can start out with, you know, four to six months ADT for generally unfavorable intermediate risk prostate cancer. What agents, any kind of major preference? And maybe I'll just throw this out there.

You know, once upon a time when I was prescribing a lot of ADT, I was like, let's give you a six month shot of Lupron. Let's be done with it. It's cost effective, rock and roll. And there's baked in compliance. Now, I'm not saying that that's the best route, but let's just talk about an intermediate risk patient that's getting ADT coming into your office. And what does that conversation look like?

You know, once upon a time when I was prescribing a lot of ADT, I was like, let's give you a six month shot of Lupron. Let's be done with it. It's cost effective, rock and roll. And there's baked in compliance. Now, I'm not saying that that's the best route, but let's just talk about an intermediate risk patient that's getting ADT coming into your office. And what does that conversation look like?

You know, once upon a time when I was prescribing a lot of ADT, I was like, let's give you a six month shot of Lupron. Let's be done with it. It's cost effective, rock and roll. And there's baked in compliance. Now, I'm not saying that that's the best route, but let's just talk about an intermediate risk patient that's getting ADT coming into your office. And what does that conversation look like?

You know, while I think we like to get those durations of ADT in for the intermediate risk patients and for the high risk patients, it's kind of a little bit of a conversation, right? If they're completely miserable and life is not worth living, then it's not like we're going to strap you down and get you two years in.